share_log

Avenue Therapeutics | UPLOAD: Others

Avenue Therapeutics | UPLOAD: Others

Avenue Therapeutics | UPLOAD:其他
美股sec公告 ·  05/08 12:46
Moomoo AI 已提取核心訊息
Avenue Therapeutics, Inc. has been informed by the Division of Corporation Finance Office of Life Sciences that the United States Securities and Exchange Commission (SEC) will not review the company's Registration Statement on Form S-3, which was filed on May 6, 2024. The SEC's communication, dated May 8, 2024, was addressed to Dr. Alexandra MacLean, CEO of Avenue Therapeutics. The SEC also reminded the company of its responsibility for the accuracy and adequacy of disclosures, irrespective of the SEC's review process. The SEC provided contact information for any further questions and referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process.
Avenue Therapeutics, Inc. has been informed by the Division of Corporation Finance Office of Life Sciences that the United States Securities and Exchange Commission (SEC) will not review the company's Registration Statement on Form S-3, which was filed on May 6, 2024. The SEC's communication, dated May 8, 2024, was addressed to Dr. Alexandra MacLean, CEO of Avenue Therapeutics. The SEC also reminded the company of its responsibility for the accuracy and adequacy of disclosures, irrespective of the SEC's review process. The SEC provided contact information for any further questions and referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process.
公司已收到生命科學辦公室的企業融資部的通知,美國證券交易所(SEC)將不會審核於2024年5月6日提交的S-3表格的申請文件,此信件發出日期是2024年5月8日,收信人爲Avenue Therapeutics的CEO Alexandra MacLean女士。SEC還提醒公司不論SEC審核結果如何,披露信息的準確性和充分性都由公司負責。SEC給出了進一步諮詢的聯繫方式,並提及了規則460和461,這些規則涉及請求加快註冊流程的事項。
公司已收到生命科學辦公室的企業融資部的通知,美國證券交易所(SEC)將不會審核於2024年5月6日提交的S-3表格的申請文件,此信件發出日期是2024年5月8日,收信人爲Avenue Therapeutics的CEO Alexandra MacLean女士。SEC還提醒公司不論SEC審核結果如何,披露信息的準確性和充分性都由公司負責。SEC給出了進一步諮詢的聯繫方式,並提及了規則460和461,這些規則涉及請求加快註冊流程的事項。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息